Sonoma Pharmaceuticals Q2 revenue rises on strong US demand
Overview
Healthcare product maker's fiscal Q2 revenue rose 28% yr/yr, led by 93% U.S. growth
Gross margin improved to 39% from 38% on higher revenue and better manufacturing processes
Company reported first-ever positive net income before taxes, reflecting higher revenue and stable expenses
Outlook
Company anticipates potential product launch with U.S. skincare partner in summer 2027
Sonoma expects Taiwan market entry pending regulatory approval and initial purchase order
Company sees growth opportunities in senior-care market for HOCl products
Result Drivers
U.S. DEMAND - Co said 93% U.S. revenue growth was driven by higher demand and increased sales from new and existing distributors
MANUFACTURING AND CUSTOMER MIX - Co attributed higher gross margin to improved manufacturing processes and changes in customer mix
OPERATING LEVERAGE - Co said stable operating expenses alongside revenue growth demonstrated operating leverage
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | $7.20 mln | ||
Q2 EBITDA | $400,000 | ||
Q2 Gross Profit | $2.80 mln | ||
Q2 Operating Expenses | $2.50 mln |
Reuters Recommended Reads
Nov 9 - Israel's Kamada Q3 revenue up 11%, raises forecast
Nov 9 - OraSure Technologies Q3 revenue rises, gross margin improves
Nov 9 - Myomo Q3 revenue rises 22% to record high
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)